Canadian perspectives in glaucoma management: Setting target intraocular pressure range

Canadian Journal of Ophthalmology

Volumn 38, Issue 3, 2003, Pages 189-197

  Damji, Karim F ^a   Behki, Rama ^b   Wang, Lan ^a  

^a UNIVERSITY OF OTTAWA EYE INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Glaucoma; Guidelines; Intraocular pressure; Target

Indexed keywords

ANTIGLAUCOMA AGENT; ANTIHYPERTENSIVE AGENT;

ANAMNESIS; ARGON LASER; BLINDNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIODE LASER; DISEASE COURSE; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; HUMAN; INCIDENCE; INTRAOCULAR HYPERTENSION; OPEN ANGLE GLAUCOMA; PRACTICE GUIDELINE; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; TRABECULECTOMY; TRABECULOPLASTY; TREATMENT PLANNING; VISUAL FIELD;

EID: 0037767451     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/S0008-4182(03)80060-1     Document Type: Review

References (30)

1. Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol 1991;109:1090-5.
2. Leske CM, Connell AM, Wu SY, Hyman LG, Schachat AP. Risk factors for open-angle glaucoma. The Barbados Eye Study. Arch Ophthalmol 1995;113:918-24.
3. Armaly MF, Krueger DE, Maunder L, Becker B, Hetherington J Jr, Kolker AE, et al. Biostatistical analysis of the collaborative glaucoma study: 1. Summary report of the risk factors for glaucomatous visual-field defects. Arch Ophthalmol 1980;98:2163-71.
4. Palmberg P. Target IOP: How low? American Academy of Ophthalmology Subspecialty Day glaucoma meeting; 2001 Nov 10; New Orleans.
5. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130(4):429-40.
6. Collaborative Normal-Tension Glaucoma Study Group (CNTGS). The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998;126:498-505.
7. Janz NK, Wren PA, Lichter PR, Musch DC, Gillespie BW, Guire KE, et al. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology 2001;108:1954-65.
8. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120(6):701-13.
9. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-20.
10. American Academy of Ophthalmology. Preferred Practice Pattern: primary open-angle glaucoma. San Francisco: The Academy; 1989.
11. European Glaucoma Society. Terminology and guidelines for glaucoma. Savona (Italy): The Society; 1998.
12. Brubaker RF. Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. Am J Ophthalmol 1996;121(5):473-83.
13. Hodapp E, Parrish RP, Anderson D. Clinical decisions in glaucoma. St Louis: CV Mosby Company; 1993. p. 65.
14. American Academy of Ophthalmology. Preferred Practice Pattern: primary open-angle glaucoma. San Francisco: The Academy; 2000.
15. Shirakashi M, Iwata K, Sawaguchi S, Abe H, Nanba K. Intraocular pressure-dependent progression of visual field loss in advanced primary open-angle glaucoma: a 15-year follow-up. Ophthalmologica 1993;207:1-5.
16. Odberg T. Visual field prognosis in advanced glaucoma. Acta Ophthalmol 1987;182(Suppl 65):27-9.
17. Jampel HD. Target pressure in glaucoma therapy. J Glaucoma 1997;6:133-8.
18. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000;9:134-42.
19. Whitacre MM, Stein R. Sources of error with use of Goldmann-type tonometers. Surv Ophthalmol 1993;38:1-30.
20. American Academy of Ophthalmology. Summary benchmarks for Preferred Practice Patterns. San Francisco: The Academy; 2000. Available: www.aao.org/aao/education/library/benchmarks.cfm (accessed 2002 July 31).
21. Quigley HA, Brown AE, Morrison JD, Drance SM. The size and shape of the optic disc in normal human eyes. Arch Ophthalmol 1990;108:51-7.
22. Grant WM, Burke JF. Why do some people go blind from glaucoma? Ophthalmology 1982;89:991-8.
23. Suzuki Y, Shirato S, Adachi M, Hamada C. Risk factors for the progression of treated primary open-angle glaucoma: a multivariate life-table analysis. Graefes Arch Clin Exp Ophthalmol 1999;237:463-7.
24. Kolker AE. Visual prognosis in advanced glaucoma: a comparison of medical and surgical therapy for retention of vision in 101 eyes with advanced glaucoma. Trans Am Ophthalmol Soc 1977;75:539-55.
25. Wilson R, Walker AM, Dueker DK, Crick RP. Risk factors for rate of progression of glaucomatous visual field loss. Arch Ophthalmol 1982;100:737-41.
26. Stewart WC, Kolker AE, Sharpe ED, Day DG, Holmes KT, Leech JN, et al. Factors associated with long-term progression or stability in primary open-angle glaucoma. Am J Ophthalmol 2000;130:274-9.
27. Drance S, Anderson DR, Schulzer M, for the Collaborative Normal-Tension Glaucoma Study Group. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol 2001;131: 699-708.
28. Graham SL, Drance SM. Nocturnal hypotension: role in glaucoma progression. Surv Ophthalmol 1999;43(Suppl 1):S10-6.
29. Stewart WC, Chorak RP, Hunt HH, Sethuraman G. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol 1993;116:176-81.
30. Ishida K, Yamamoto T, Kitazawa Y. Clinical factors associated with progression of normal-tension glaucoma. J Glaucoma 1998;7:372-7.